Raymond James Financial Reiterates “Hold” Rating for Galena Biopharma (GALE)

Galena Biopharma (NASDAQ:GALE)‘s stock had its “hold” rating restated by stock analysts at Raymond James Financial in a note issued to investors on Monday.

Shares of Galena Biopharma (NASDAQ:GALE) opened at $0.28 on Monday. Galena Biopharma has a 12-month low of $0.26 and a 12-month high of $3.60.

A number of institutional investors have recently made changes to their positions in GALE. Renaissance Technologies LLC purchased a new stake in Galena Biopharma during the 1st quarter worth $976,000. Vaughan David Investments Inc. IL boosted its position in Galena Biopharma by 6,545.7% during the 3rd quarter. Vaughan David Investments Inc. IL now owns 864,076 shares of the biotechnology company’s stock worth $20,893,000 after purchasing an additional 851,074 shares during the period. Virtu KCG Holdings LLC boosted its position in Galena Biopharma by 677.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 195,230 shares during the period. Finally, Vanguard Group Inc. boosted its position in Galena Biopharma by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock worth $774,000 after purchasing an additional 13,302 shares during the period. 18.51% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://sportsperspectives.com/2017/12/20/raymond-james-financial-reiterates-hold-rating-for-galena-biopharma-gale.html.

About Galena Biopharma

Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.

Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply